Skip to main content

Advertisement

SpringerLink
Log in

Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren’s disease

  • Orthopaedic Surgery
  • Published:
Archives of Orthopaedic and Trauma Surgery Aims and scope Submit manuscript

Abstract

Introduction

Dupuytren’s disease is a fibroproliferative disorder characterized by thickening of the palmar fascia. Several studies indicate that MMPs and TIMPs may play a key role in the onset or progression of Dupuytren’s disease and related disorders. In this study, we used a quantitative reverse-transcription PCR methodology to profile the expression of TIMP1, TIMP2, MMP2, and MMP9 in nodule and cord tissue from patients with Dupuytren’s disease and compared this with normal palmar fascia taken at carpal tunnel release.

Materials and methods

Tissue from patients with Dupuytren’s disease was taken at fasciectomy (n = 30; 23 men and 7 women; average age 61.3 ± 9.5 years). Samples were divided into regions of nodule and cord according to gross morphology. Normal fascia was taken from patients without Dupuytren’s contracture who had carpal tunnel release (n = 30; 14 men and 16 women; average age 63 ± 11 years). Expression of mRNA was calculated using a relative quantification method (Pfaffl). Statistical analysis was performed using the Mann–Whitney test. The level of significance was considered to be P < 0.05.

Results

In comparison to normal fascia, the cords and nodules from patients with Dupuytren’s disease showed significant upregulation for TIMP1 and TIMP2 (P < 0.05). The expression of TIMP1 was significantly higher in nodules in comparison to cord tissue (P < 0.05). The expression of MMP2 was significantly upregulated in tissue of patients with Dupuytren’s contracture in comparison to normal tissue (P < 0.05). The expression of MMP2 was significantly higher in nodules in comparison to cord tissue (P < 0.05). There was no significant difference in the relative expression of MMP9 in nodules and cord tissue of patients with Dupuytren’s contracture in comparison to normal fascia from patients with carpal tunnel syndrome.

Conclusions

The balance between MMPs and their natural inhibitors is disturbed in patients with Dupuytren’s disease. The decrease in MMP-to-TIMP expression can cause increased synthesis and deposition of collagen, leading to palmar fibromatosis. The high expression of MMP2 may represent an unsuccessful attempt to reduce collagen deposition. In the future, a treatment that downregulates TIMPs but increases the activity of MMPs may be an appropriate therapy for Dupuytren’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Al-Qattan MM (2006) Factors in the pathogenesis of Dupuytren’s contracture. J Hand Surg 31A:1527–1534

    Google Scholar 

  2. Augoff K, Ratajczak K, Gosk J, Tabola R, Rutowski R (2006) Gelatinase A activity in Dupuytren’s disease. J Hand Surg 31A:1635–1639

    Google Scholar 

  3. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K (1996) The role of transforming growth factor beta in Dupuytren’s disease. J Hand Surg 21A:210–215

    Google Scholar 

  4. Badalamente MA, Hurst LC (1999) The biochemistry of Dupuytren’s disease. Hand Clin 15:35–42

    PubMed  CAS  Google Scholar 

  5. Badalamente MA, Hurst LC (2000) Enzyme injection as non-surgical treatment of Dupuytren’s disease. J Hand Surg (Am) 25:629–636

    Article  CAS  Google Scholar 

  6. Badalamente MA, Hurst LC (2007) Efficacy and safety of injectable mixed collagenases subtypes in the treatment of Dupuytren’s contracture. J Hand Surg (Am) 32:767–774

    Article  Google Scholar 

  7. Berndt A, Kosmehl H, Mandel U et al (1995) TGF beta and bFGF synthesis and localization in Dupuytren’s disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 27:1014–1020

    PubMed  CAS  Google Scholar 

  8. Brenner P (2002) Dupuytren’s disease of ring and little finger. Orthop Traumatol 10:138–158

    Article  Google Scholar 

  9. Brew K, Dinakarpandian D, Nagase H (2002) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267

    Google Scholar 

  10. Brinckerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3:207–214

    Article  PubMed  CAS  Google Scholar 

  11. Burge P, Hoy G, Regan P, Milne R (1997) Smoking, alcohol and the risk of Dupuytren’s contracture. J Bone Joint Surg (Br) 79:206–210

    Article  CAS  Google Scholar 

  12. Cordova A, Tripoli M, Corradino B, Napoli P, Moschella F (2005) Dupuytren’s contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg (Br) 30(6):557–562

    CAS  Google Scholar 

  13. Forbes JM, Thallas V, Tomas MC et al (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17:1762–1764

    PubMed  CAS  Google Scholar 

  14. Hoegemann A, Wolfhard U, Kendoff D, Board TN, Olivier LC (2008) Results of total aponeurectomy for Dupuytren’s contracture in 61 patients. A retrospective clinical study. Arch Orthop Trauma Surg, 31 May (Epub ahead of print)

  15. Hurst LC, Badalamente MA (1999) Nonoperative treatment of Dupuytren’s disease. Hand Clinics 15:97–107

    PubMed  CAS  Google Scholar 

  16. Hutchinson JW, Tierney GM, Parsons SL, Davis TR (1998) Dupuytren’s disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg 80B:907–908

    Article  Google Scholar 

  17. Imai K, Hiramatsu A, Fukushima D, Pierschabacher D, Okada Y (1997) Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. Biochem J 322:809–814

    PubMed  CAS  Google Scholar 

  18. Johnston P, Chojnowski AJ, Davidson RK et al (2007) A complete expression profile of matrix-degrading metalloproteinases in Dupuytren’s disease. J Hand Surg (Am) 32:343–351

    Article  Google Scholar 

  19. Kloen P (1999) New insights in the development of Dupuytren’s contracture: a review. Br J Plast Surg 52:629–635

    Article  PubMed  CAS  Google Scholar 

  20. Luck JV (1959) Dupuytren’s contracture: a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg (Am) 41:635–664

    Google Scholar 

  21. Massova I, Kotra LP, Fridman R, Mobashery S (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 12:1075–1095

    PubMed  CAS  Google Scholar 

  22. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558–564

    Article  PubMed  CAS  Google Scholar 

  23. Moyer KE, Banducci DR, Graham WP 3rd, Ehrlich HP (2002) Dupuytren’s disease: physiologic changes in nodule and cord fibroblasts through aging in vitro. Plast Reconstr Surg 110:187–193

    Article  PubMed  Google Scholar 

  24. Murrell GAC, Francis MJO, Bromley L (1991) The collagen changes of Dupuytren’s contracture. J Hand Surg (Br) 16:263–266

    CAS  Google Scholar 

  25. Nagase H, Woessner JF (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494

    Article  PubMed  CAS  Google Scholar 

  26. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562–573

    Article  PubMed  CAS  Google Scholar 

  27. Pan D, Watson HK, Swigart C, Thomson JG, Honig SC, Narayan D (2003) Microarray gene analysis and expression profiles of Dupuytren’s contracture. Ann Plast Surg 50:618–622

    Article  PubMed  Google Scholar 

  28. Patterson ML, Atkinson SJ, Knäuper V, Murphy G (2003) Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett 503:158–162

    Article  Google Scholar 

  29. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF (2004) Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology 64:399–404

    Article  PubMed  CAS  Google Scholar 

  30. Ramadori G, Knittel T, Saile B (1998) Fibrosis and altered matrix synthesis. Digestion 59:372–375

    Article  PubMed  CAS  Google Scholar 

  31. Ravanti L, Kahari VM (2000) Matrix metalloproteonases in wound repair. Int J Mol Med 6:391–407

    PubMed  CAS  Google Scholar 

  32. Rayan GM (2007) Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg (Am) 89:189–198

    Google Scholar 

  33. Reynolds JJ (1996) Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation. Oral Dis 2:70–76

    PubMed  CAS  Google Scholar 

  34. Satish L, LaFramboise WA, O’Gorman DB et al (2008) Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren’s contracture. BMC Med Genomics 1:10

    Article  PubMed  Google Scholar 

  35. Shaw RB, Chong AKS, Zhang A, Hentz VR, Chang J (2007) Dupuytren’s disease: history, diagnosis, and treatment. Plast Reconstr Surg 120:44e–54e

    Article  PubMed  Google Scholar 

  36. Smeets R, Ulrich D, Unglaub F, Wöltje M, Pallua N (2008) Effect of regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration. Int Wound J 5:195–203

    Article  PubMed  Google Scholar 

  37. Smith SP, Devaraj VS, Bunker TD (2001) The association between frozen shoulder and Dupuytren’s disease. J Shoulder Elbow Surg 10:149–151

    Article  PubMed  CAS  Google Scholar 

  38. Starkweather KD, Lattuga S, Hurst LC et al (1996) Collagenase in the treatment of Dupuytren’s disease: an in vitro study. J Hand Surg (Am) 21:490–495

    Article  CAS  Google Scholar 

  39. Swartz WM, Lalonde DH (2008) MOC-PSSM CME Article: Dupuytren’s disease. Plast Reconstr Surg 121:1–10

    Article  PubMed  Google Scholar 

  40. Tarlton JF, Meagher P, Brown RA, McGrouther DA, Bailey AJ, Afoke A (1998) Mechanical stress in vitro induces increased expression of MMPs 2 and 9 in excised Dupuytren’s disease tissue. J Hand Surg 23B:297–302

    Google Scholar 

  41. Ulrich D, Hrynyschyn K, Pallua N (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinase in sera and tissue of patients with Dupuytren’s disease. Plast Reconstr Surg 112:1279–1286

    Article  PubMed  Google Scholar 

  42. Ulrich D, Noah EM, von Heimburg D, Pallua N (2003) TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast Reconstr Surg 111:1423–1431

    Article  PubMed  Google Scholar 

  43. Ulrich D, Lichtenegger F, Eblenkamp M, Repper D, Pallua N (2004) Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with TRILUCENT breast implants. Plast Reconstr Surg 114:229–236

    Article  PubMed  Google Scholar 

  44. Unemori EN, Beck LS, Lee WP et al (1993) Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J Invest Dermatol 101:280–285

    Article  PubMed  CAS  Google Scholar 

  45. Unemori EN, Pickford LB, Al Salles et al (1996) Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 98:2739–2745

    Article  PubMed  CAS  Google Scholar 

  46. Unglaub F, Loos B, Schwarz S, Kneser U, Dragu A, Horch RE (2008) Phlegmonous-infection in first degree Dupuytren’s disease. Arch Orthop Trauma Surg, 20 March (Epub ehead of print)

  47. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839

    Article  PubMed  CAS  Google Scholar 

  48. Vu TH, Werb Z (2000) Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14:2123–2133

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Plastic Surgery, Hand Surgery, Burn Unit, University Hospital, Medical Faculty of the University of Technology, Aachen University of Technology, Pauwelsstrasse 30, 52074, Aachen, Germany

    Dietmar Ulrich, Andrzej Piatkowski & Norbert Pallua

  2. Department of Plastic, Reconstructive and Hand Surgery, Caritas Hospital St. Josef, Landshuter Strasse 65, 93047, Regensburg, Germany

    Franziska Ulrich

Authors
  1. Dietmar Ulrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franziska Ulrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrzej Piatkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norbert Pallua
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dietmar Ulrich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ulrich, D., Ulrich, F., Piatkowski, A. et al. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren’s disease. Arch Orthop Trauma Surg 129, 1453–1459 (2009). https://doi.org/10.1007/s00402-008-0726-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00402-008-0726-3

Keywords

Search

Navigation